J&J axes pair of CAR-T therapies for lymphoma, citing evolving market
Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and antibody-based drugs addressing the disease. The drugmaker
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · finance
- [FINANCE] [Editorial] Creating a smoke-free generation
- [FINANCE] Dollar Stays on the Back Foot as Markets Embrace Risk and Look Past Geopolitics - Action Forex
- [FINANCE] Non-Farm Payroll Week Ahead: Global Market Outlook Amid Labor Market Data Dynamics - Moomoo
- [FINANCE] US Treasury yields fall on reports Iran sent its latest proposal for negotiations with the US to Pakistani mediators - marketscreener.com
- [FINANCE] SoftBank-Backed Opay Hires Citi, Deutsche, JPMorgan for US IPO - Bloomberg.com
- [FINANCE] Esperion Stock Pops On Billion-Dollar ARCHIMED Buyout - Benzinga